Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis

Palmerini, 2015, Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis, J Am Coll Cardiol, 65, 2496, 10.1016/j.jacc.2015.04.017 Camenzind, 2007, Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern, Circulation, 115, 1440, 10.1161/CIRCULATIONAHA.106.666800 Woudstra, 2016, 1-Year results of the REMEDEE registry: clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered (COMBO) stent in a multicenter, prospective all-comers registry, JACC Cardiovasc Interv, 9, 1127, 10.1016/j.jcin.2016.02.052 Nakazawa, 2008, Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study, Circulation, 118, 1138, 10.1161/CIRCULATIONAHA.107.762047 Finn, 2007, Vascular responses to drug eluting stents: importance of delayed healing, Arterioscler Thromb Vasc Biol, 27, 1500, 10.1161/ATVBAHA.107.144220 Alazzoni, 2012, Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials, Thrombosis, 2012, 10.1155/2012/126369 Iakovou, 2005, Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents, JAMA, 293, 2126, 10.1001/jama.293.17.2126 Mehran, 2016, “Capturing” the benefits of dual-therapy stent technology: is this a promise or reality?, JACC Cardiovasc Interv, 9, 1135, 10.1016/j.jcin.2016.03.035 Granada, 2010, Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix, Circ Cardiovasc Interv, 3, 257, 10.1161/CIRCINTERVENTIONS.109.919936 Lee, 2016, Circ Cardiovasc Interv, 9, 10.1161/CIRCINTERVENTIONS.115.003469 Kalkman, 2017, Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis, EuroIntervention, 13, 1202, 10.4244/EIJ-D-17-00301 Kalkman, 2017, Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome, Catheter Cardiovasc Interv, 90, E31, 10.1002/ccd.26915 Saito, 2018, Eur Heart J, 39, 2460, 10.1093/eurheartj/ehy275 Haude, 2013, The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent, JACC Cardiovasc Interv, 6, 334, 10.1016/j.jcin.2012.10.018 Jaguszewski, 2017, JACC Cardiovasc Interv, 10, 489, 10.1016/j.jcin.2016.11.040 Kalkman, 2017, Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry, Open Heart, 4, 10.1136/openhrt-2017-000634 Moher, 1999, Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Ann Intern Med, 151, 264, 10.7326/0003-4819-151-4-200908180-00135 Higgins, 2016, A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods, Cochrane Database Syst Rev, 10 Sterne, 2016, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ, 355 Stone, 2011, Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial, J Am Coll Cardiol, 58, 19, 10.1016/j.jacc.2011.02.022 Kedhi, 2010, Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial, Lancet, 375, 201, 10.1016/S0140-6736(09)62127-9 Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, McLaurin BT, Popma JJ, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. (1558–3597 (Electronic)). Serruys, 2010, Comparison of zotarolimus-eluting and everolimus-eluting coronary stents, N Engl J Med, 363, 136, 10.1056/NEJMoa1004130 Larsen, 2012, Capture of circulatory endothelial progenitor cells and accelerated re-endothelialization of a bio-engineered stent in human ex vivo shunt and rabbit denudation model, Eur Heart J, 33, 120, 10.1093/eurheartj/ehr196 Lee, 2018, The newest generation of drug-eluting stents and beyond, Eur Cardiol, 13, 54, 10.15420/ecr.2018:8:2